Insmed Incorporated filings document formal disclosures for its commercial biopharmaceutical portfolio and respiratory and inflammatory pipeline. Recent Form 8-K reports furnish financial results, investor presentations, Regulation FD materials, clinical-study updates for ARIKAYCE and brensocatib, regulatory approval announcements for BRINSUPRI, and portfolio additions such as INS1148.
The company’s proxy materials describe board elections, executive compensation, equity awards, shareholder voting matters and governance practices. Other current reports document compensatory arrangements, director-transition disclosures, exhibits and Inline XBRL cover-page data tied to Insmed’s Nasdaq-listed common stock.
INSMED Inc Chair and CEO William Lewis reported option exercises and share sales in INSMED common stock. On June 25, 2026, he exercised stock options covering 21,398 shares at strike prices of $17.16 and $30.46 per share, converting derivative awards into common stock.
On the same date, he sold 21,398 shares in multiple open-market transactions at weighted average prices ranging from about $101.78 to $106.45 per share, pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on September 4, 2025. After these transactions, Lewis holds 258,917 shares directly and 233,924 shares indirectly through a trust.
INSMED Inc officer William Lewis reported a proposed sale of 21,398 common shares, with an aggregate market value of $2,210,653 and an approximate sale date of June 25, 2026. The listed Rule 10b5-1 plan adoption or instruction date is September 4, 2025.
INSMED Inc senior vice president Samuele Butera received new equity awards as part of his compensation. He was granted 7,342 Restricted Stock Units, each representing one future share of common stock, with 25% vesting on the first day of the first month after the first anniversary of grant and the remainder vesting in three annual installments.
He was also granted stock options for 12,570 shares of common stock at an exercise price of $102.15 per share, expiring on June 23, 2036. These options vest 25% on the initial vesting date and 12.5% every six months thereafter until fully vested. All awards were granted for no cash consideration.
INSMED Inc executive files initial insider report with no transactions. Samuele Butera, listed as SVP, GM, Global Respiratory at INSMED Inc, is identified as a reporting person on a Form 3. The filing shows zero buy, sell, acquisition, or disposition transactions, and no derivative positions or holdings are reported.
INSMED Inc Chief Legal Officer Michael Alexander Smith sold 1,806 shares of Common Stock in an open-market transaction. The shares were sold at a price of $95.82 per share. After this sale, he directly holds 37,648 shares of INSMED Inc Common Stock.
The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which means the timing and amount were set in advance rather than decided at the moment of sale.
Michael Smith, an officer of INSMED Inc, reported a proposed sale of 1,806 common shares, with an aggregate market value of $173,039, through Merrill Lynch, for approximately June 22, 2026. The notice gives November 7, 2025 as the Rule 10b5-1 plan adoption or instruction date. It also lists four earlier sales by Smith from March 30 through June 3, 2026.
INSMED Inc Chair and CEO William Lewis reported an open-market sale of 6,515 shares of Common Stock. The shares were sold at a price of $94.03 per share. After this transaction, he directly holds 258,917 shares of Common Stock.
The filing also shows an indirect holding of 233,924 shares of Common Stock held by a trust. According to a footnote, the sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 4, 2025, indicating it was scheduled in advance.
INSMED Inc officer William Lewis reported a proposed sale of 6,515 common shares, with an aggregate market value of $612,576, on approximately June 8, 2026. The 6,515 shares were acquired from the issuer through stock plan activity on June 1, 2026. The reported date of plan adoption or giving of instruction, if relying on Rule 10b5-1, is September 4, 2025.
INSMED Inc officer Martina Flammer reported a planned sale of 1,858 common shares, with an aggregate market value of $192,811 and an approximate sale date of June 5, 2026. The shares are listed as acquired from the issuer through stock plan activity on June 1, 2026. The planned sale is associated with a Rule 10b5-1 plan adopted February 27, 2025.
INSMED Inc Chief Operating Officer Roger Adsett reported a sale of 2,370 shares of common stock. The shares were sold at an average price of $102.27 per share to satisfy tax withholding obligations related to the vesting of Restricted Stock Units and to cover associated broker fees. After this transaction, Adsett directly holds 98,603 shares of INSMED common stock, indicating this was a routine, tax-driven disposition rather than a discretionary reduction in his equity stake.